UCB is a global biopharmaceutical company focused on creating solutions for neurological and autoimmune conditions.

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

UCB SA

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Dec 5, 2024 6:38 PM	ff5f05da
public peers	general	Sep 25, 2024 1:07 PM	486a9cd1
news daily refresh	general	Dec 23, 2024 12:00 AM	a78a4fd8
news processing daily refresh	general	Dec 20, 2024 8:04 PM	79b3c7ef
news impact assignment daily	general	Dec 20, 2024 7:59 AM	1c53d840
news processing basic	general	Dec 4, 2024 6:21 PM	46f3cbfb
company summary	general	Dec 20, 2024 10:54 AM	e2bad638
signals	general	Sep 25, 2024 1:07 PM	9d7ab350
crunchbase trigger	general	Nov 27, 2024 12:50 PM	3b18298a
crunchbase profile	general
li profile	general
translate crunchbase fundingrounds	general
peers	general	Sep 25, 2024 1:07 PM	a37c63fc
news basic	general	Dec 4, 2024 2:13 PM	627ac6b1
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:UCB

UCB

Last Close

180.00

25/11 09:25

Market Cap

27.52B

Beta: -

Volume Today

23.29K

Avg: -